July 7, 2026 -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed financing round led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio and existing investor SFC Capital. Proceeds will support pre-clinical development, manufacturing scale-up, regulatory engagement with the MHRA and FDA, and progression toward first-in-h

Financing brings together a syndicate of top-tier healthcare investors, including RA Capital Management, Leaps by Bayer, and Celea founder PureTech Health, alongside a large, US-based healthcare-focused fund and a leading sovereign wealth fund Proceeds will enable early Q3 2026 initiation of SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone vs. pirfenidone Celea Therapeutics ("Celea" or the "Company"), a clinical-stage biopharmaceutical company d

PureTech launches Celea as an independent company backed by a syndicate of top-tier healthcare investors, enabling PureTech’s transition to a lean operating model PureTech retains 35.4% ownership of Celea in addition to non-dilutive royalties, milestone payments, and sublicense income, maintaining long-term potential upside Proceeds enable Celea to initiate SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone as a potential new standard of care Pure

Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biology July 1, 2026 -- ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role as Co-Founder and Chief Executive Officer of CrossBridge Bio through its acquisition by Eli Lilly. The financing will su

The star of Ipsen’s acquisition is an MDM2 blocker being proposed as an add-on therapy to ruxolitinib for myelofibrosis. The drug could be available to patients “as early as 2028,” according to Ipsen CEO David Loew. Ipsen will absorb California-based Kartos Therapeutics in a back-heavy agreement that will give the French biotech a late-stage drug candidate for a rare blood cancer. The deal involves a $450 million upfront payment from Ipsen, according to a news release on Monday morning. The co

Imagion Biosystems, Ltd. (ASX: IBX) announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA’s clearance of the company’s IND application for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the MagSense® imaging agent in HER2+ breast cancer. The company has already begun trial activation activities and expects to begin patient recruitment later this year. “We are very pleased with the strong demand we saw fro

June 25, 2026 -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. Pursuant to the definitive agreement, the Samsung entities invested $110 million in GRAIL through the purchase of shares of GRAIL common stock at a price of $70.05 per share, representing a long-term investment in support of GRAIL's growth

Novartis will pay biotechnology startup Antares Therapeutics $105 million as part of a multi-target research collaboration to find the Swiss pharmaceutical giant new cancer medicines. According to the terms of the dealannounced Wednesday, Antares stands to gain as much as $1.8 billion in additional payments if it discovers worthwhile targets and hits certain development and commercialization milestones. It’s also eligible for tiered royalties in “the low double-digit range” on resulting products

June 22, 2026 -- NanoGhost Ltd., a biotechnology company developing a proprietary targeted drug delivery platform for cancer and other severe diseases, announced today that it has been awarded a new grant from the Israel Innovation Authority to support an innovative collaborative research program with Ben-Gurion University of the Negev via its technology transfer company, BGN. This marks the sixth grant awarded to NanoGhost by the Israel Innovation Authority, reflecting continued confidence in

New funding will power foundational primary cell data generation to advance AI-driven discovery through the company's full product launch. June 22, 2026 -- DropGenie, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first product. The round was led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM, and existing investors Real Ventures and Anges Québec continuin